78O - Immune microenvironment of small-cell lung cancer (SCLC): distribution of PD-L1 expression and prognostic role of FOXP3-positive tumor infiltrating...

Date 12 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session PD-L1 expression and tumor microenvironment in advanced lung cancer
Topics Small-Cell Lung Cancer
Cancer Immunology and Immunotherapy
Lung and other Thoracic Tumours
Presenter Alberto Pavan
Citation Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.
Authors A. Pavan1, M. Fassan2, M.V. Dieci1, I. Attili1, G. Pasello1, F. Calabrese3, F. Rea4, M. Rugge2, P.F. Conte1, L. Bonanno1
  • 1Medical Oncology 2, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 2Cytology And Pathology, Surgical, Oncological And Gastroenterological Sciences, Azienda Ospedaliera di Padova Università, Padova/IT
  • 3Cardiothoracic And Vascular Sciences, Patholology, Padova/IT
  • 4Cardiothoracic And Vascular Sciences, Thoracic Surgery, Padova/IT


SCLC represents one of the most aggressive lung malignancies, characterized by a high growth fraction and early metastatic spread. New therapeutic options are badly needed and immunotherapy might represent a promising approach. Unfortunately, so far, no molecular prognostic markers have been validated for clinical practice and data on immune microenvironment are limited.